Polyphor bags second grant in two years for a new class of antibiotics to fight drug-resistant bacteria
A year after receiving its first grant from Boston University’s CARB-X partnership, Swiss biotech Polyphor is back for more. It recently bagged a second award of up to $18.44 million for work on what it calls a new class of antibiotics to fight drug-resistant Gram-negative bacteria.
The grant includes $2.62 million for Polyphor’s “hit-to-lead” stage and $15.82 million in milestones.
Polyphor calls its class of antibiotics, discovered with the University of Zurich, Outer Membrane Protein Targeting Antibiotics (OMPTA). They target the lipopolysaccharide transport protein A, and have shown antimicrobial activity against drug-resistant strains of Enterobacteriaceae, which are among the WHO’s priority-1 pathogens, according to Polyphor.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
